Anzeige
Mehr »
Dienstag, 26.08.2025 - Börsentäglich über 12.000 News
Breaking: AlsetAI zündet nächste Stufe - Neue Allianz mit CHIP Datacentres & Hochkarätige Vorstände markieren Wendepunkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQWL | ISIN: US60458C1045 | Ticker-Symbol: K6S
Frankfurt
26.08.25 | 09:59
1,170 Euro
-2,50 % -0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MIRA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MIRA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1901,25010:45
1,1901,25010:29

Aktuelle News zur MIRA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.08.MIRA Pharmaceuticals schließt Phase-1-SAD-Studie für Schmerzmittel ab2
19.08.MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage362Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)...
► Artikel lesen
19.08.Mira Pharmaceuticals schließt Phase-1-Studie für Ketamir-2 ohne Sicherheitsbedenken ab2
19.08.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report2
12.08.MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin211Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism"...
► Artikel lesen
12.08.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report2
30.07.MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study282Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain...
► Artikel lesen
MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.07.MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain336Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end MIAMI, FLORIDA...
► Artikel lesen
28.07.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report2
11.07.MIRA Pharmaceuticals: MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition334SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier...
► Artikel lesen
10.07.Mira Pharmaceuticals: Präklinische Daten für SKNY-1 deuten auf angstlösende Wirkung hin3
10.07.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report3
08.07.MIRA Pharmaceuticals sichert sich 2 Millionen US-Dollar durch Block-Verkauf von Aktien14
03.07.MIRA Pharmaceuticals: MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks326With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)...
► Artikel lesen
03.07.MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours10
02.07.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report5
30.06.Mira Pharmaceuticals berichtet über Ergebnisse von Tierstudien für SKNY-1 Abnehmmittel5
30.06.MIRA Pharmaceuticals: MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition288Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA)...
► Artikel lesen
30.06.EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study2
25.06.MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects291MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for...
► Artikel lesen
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1